ZymeworksZYME
ZYME
About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Employees: 290
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
106% more call options, than puts
Call options by funds: $547K | Put options by funds: $266K
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
17% more capital invested
Capital invested by funds: $833M [Q3] → $973M (+$140M) [Q4]
6% more funds holding
Funds holding: 162 [Q3] → 171 (+9) [Q4]
2.96% more ownership
Funds ownership: 93.48% [Q3] → 96.45% (+2.96%) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 61
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
4%
upside
Avg. target
$16
19%
upside
High target
$18
34%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Wells Fargo Derek Archila 47% 1-year accuracy 17 / 36 met price target | 4%upside $14 | Equal-Weight Maintained | 19 Dec 2024 |
JP Morgan Brian Cheng 6% 1-year accuracy 1 / 18 met price target | 34%upside $18 | Overweight Upgraded | 16 Dec 2024 |
Financial journalist opinion
Based on 5 articles about ZYME published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced achievement of a $14 million cash research milestone from GSK associated with a clinical milestone.
Neutral
GlobeNewsWire
3 days ago
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
1 week ago
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development.
Neutral
GlobeNewsWire
2 weeks ago
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results after market close on March 5, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 5, 2025 at 4:30 pm Eastern Time (ET).
Neutral
GlobeNewsWire
4 weeks ago
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
Positive
Seeking Alpha
1 month ago
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Neutral
GlobeNewsWire
1 month ago
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
VANCOUVER, British Columbia, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today provided an update on key strategic priorities for 2025 and 2026.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade
The mean of analysts' price targets for Zymeworks (ZYME) points to a 41.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Seeking Alpha
2 months ago
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks should start generating royalties on net sales this quarter. The phase 3 results for Ziihera in first-line GEA patients are now expected in Q2 2025, and represent the next critical step for Zymeworks and its partner Jazz.
Neutral
GlobeNewsWire
3 months ago
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
Charts implemented using Lightweight Charts™